<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The advantage of platelet integrin GPIIb-IIIa receptor <z:chebi fb="68" ids="48706">antagonists</z:chebi> in the prevention of thrombotic occlusion was clearly proven in patients who underwent interventional treatment of the coronary artery, but its value in <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> is still under investigation </plain></SENT>
<SENT sid="1" pm="."><plain>The expectation of <z:hpo ids='HP_0002170'>intracranial hemorrhage</z:hpo> on strong inhibition of platelet function restricts its application in <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>To minimize <z:mp ids='MP_0001914'>bleeding</z:mp> while keeping antithrombotic activity, we have tried to find an appropriate approach using a combination of platelet integrin GPIIb-IIIa receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi> and some other antithrombotic agents </plain></SENT>
<SENT sid="3" pm="."><plain>The time to thrombotic occlusion was measured using a photothrombotic occlusion model of guinea pig middle cerebral artery </plain></SENT>
<SENT sid="4" pm="."><plain>A platelet integrin GPIIb-IIIa receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi>, ME3277 (<z:chebi fb="199" ids="26708">sodium</z:chebi> hydrogen [4-[(4,5,6,7-tetrahydrothieno [3,2-c] <z:chebi fb="0" ids="51641">pyridin-2-yl</z:chebi>) carbonylamino] <z:chebi fb="9" ids="46887">acetyl</z:chebi>-<z:chebi fb="0" ids="35448">o-phenylene</z:chebi>] dioxydiacetate), delayed occlusion time from 7.3 min in vehicle to 15.0, 20.6 and 25.9 min (P&lt;0.05) at 0.1, 0.3 and 1 mg/kg, respectively </plain></SENT>
<SENT sid="5" pm="."><plain>ME3277 profoundly inhibited ex vivo platelet aggregation and the highest dose of ME3277 prolonged (3.5 folds, P&lt;0.01) the <z:mp ids='MP_0001914'>bleeding</z:mp> time measured in the hind paw </plain></SENT>
<SENT sid="6" pm="."><plain>A <z:chebi fb="0" ids="26995">thromboxane</z:chebi> A(2) synthase inhibitor, <z:chebi fb="199" ids="26708">sodium</z:chebi> ozagrel, significantly delayed occlusion time to 19.5 min at 30 mg/kg (P&lt;0.05) while it did not affect <z:mp ids='MP_0001914'>bleeding</z:mp> time or platelet aggregation </plain></SENT>
<SENT sid="7" pm="."><plain>ME3277 (0.1 mg/kg) in combination with 10 mg/kg <z:chebi fb="199" ids="26708">sodium</z:chebi> ozagrel synergistically delayed occlusion time (<z:chebi fb="199" ids="26708">sodium</z:chebi> ozagrel alone; 7.9 min, combination; 26.1 min, P&lt;0.05 vs. ME3277 alone) </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="199" ids="26708">Sodium</z:chebi> ozagrel did not affect ex vivo platelet aggregation or <z:mp ids='MP_0001914'>bleeding</z:mp> time when combined with 0.1 mg/kg of ME3277 </plain></SENT>
<SENT sid="9" pm="."><plain>This synergy was cancelled by combination with 30 mg/kg aspirin (14.7 min) </plain></SENT>
<SENT sid="10" pm="."><plain>A <z:chebi fb="0" ids="26995">thromboxane</z:chebi> A(2) receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi>, vapiprost (0.1 mg/kg), did not enhance the antithrombotic efficacy of ME3277 </plain></SENT>
<SENT sid="11" pm="."><plain>These results imply that local prostacyclin production enhances the in vivo antithrombotic effect of the platelet integrin GPIIb-IIIa receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi> </plain></SENT>
<SENT sid="12" pm="."><plain>Therefore, the <z:chebi fb="0" ids="26995">thromboxane</z:chebi> A(2) synthase inhibitor allowed a reduction in the dose level of the platelet integrin GPIIb-IIIa receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi> for <z:hpo ids='HP_0005305'>cerebral thrombosis</z:hpo>, which resulted in a reduced risk of <z:mp ids='MP_0001914'>bleeding</z:mp> </plain></SENT>
</text></document>